Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

Summary

This study is an open-label, absorption, metabolism, excretion, and mass balance study of 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose to 6 healthy male subjects following at least a 10-hour fast (not including water) on Day 1.

Timeline

Start

2014-07

Primary completion

2014-10

Completion

2014-10

Drugs

Indications

No indication recorded.